Belite Bio (BLTE) Stock Price, News & Analysis

Company Overview

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious retinal diseases. The company’s research centers on therapies designed to address the underlying biological processes that contribute to vision loss, including the accumulation of toxic vitamin A–derived compounds in the retina.

Belite Bio’s lead product candidate is tinlarebant, also known as LBS-008. Tinlarebant is an orally administered retinol-binding protein 4 antagonist intended to reduce the delivery of vitamin A to the retina and limit the formation of toxic bisretinoids. The company is evaluating tinlarebant in Stargardt disease, an inherited retinal disorder, and geographic atrophy associated with dry age-related macular degeneration.

Founded in 2018 and headquartered in San Diego, California, Belite Bio conducts clinical development activities in multiple geographic markets. The company’s pipeline remains focused on ophthalmic diseases with significant unmet medical needs, and its product candidates are investigational and have not been established as safe or effective for commercial use.

Key Stats

• Today's Range: $168.92 to $172.22
• 50-Day Range: $146.68 to $193.61
• 52-Week Range: $68.21 to $200.00
• Volume: 93,895 shs
• Average Volume: 201,330 shs
• Market Capitalization: $6.88 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $218.73
• Consensus Rating: Moderate Buy

Belite Bio Stock Analysis - MarketRank™

Belite Bio scored higher than 73% of companies evaluated by MarketBeat, and ranked 165th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Belite Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Belite Bio has a consensus price target of $218.73, representing about 27.9% upside from its current price of $170.96.

Amount of Analyst Coverage

Belite Bio has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Belite Bio are expected to grow in the coming year, from ($3.08) to $0.91 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Belite Bio is -62.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Belite Bio is -62.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Belite Bio has a P/B Ratio of 8.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.01% of the float of Belite Bio has been sold short.

Short Interest Ratio / Days to Cover

Belite Bio has a short interest ratio ("days to cover") of 7.42.

Change versus previous month

Short interest in Belite Bio has recently decreased by 5.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Belite Bio does not currently pay a dividend.

Dividend Growth

Belite Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.77

News Sentiment

Belite Bio has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Belite Bio this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for BLTE on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Belite Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,018,474.00 in company stock.

Percentage Held by Insiders

13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.53% of the stock of Belite Bio is held by institutions.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BLTE
• CIK: 1889109
• Web: belitebio.com
• Phone: 858-246-6240
• Fax: N/A
• Employees: 41
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Belite Bio: $218.73
• High Price Target: $303.00
• Low Price Target: $132.00
• Potential Upside/Downside: +27.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -11.84%
• Return on Assets: -11.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 33.56
• Quick Ratio: 33.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $20.54 per share
• Price / Book: 8.32

Miscellaneous

• Outstanding Shares: 40,270,000
• Free Float: 34,920,000
• Market Cap: $6.88 billion
• Optionable: Not Optionable
• Beta: -1.23